Syngene International Limited
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.
What Syngene files
- Investor Meet96
- Others83
- Important38
- Updates17
- Board Meeting13
- PPTs10
Here's a concise, retail-friendly summary based on the investor presentation: **1. Business Performance:** Syngene's Q1 FY27 revenue from operations dropped 16% YoY to Rs 736 Cr. Operating EBITDA margin was 12% (down from 24% in Q1 FY26), and PAT (before exceptional items) stood at Rs 1 Cr. This was largely...
Syngene reported modest revenue growth, up 2% YoY to Rs 1,037 Cr in Q4 FY26 and 3% YoY to Rs 3,739 Cr for the full year. However, PAT before exceptional items declined 16% to Rs 153 Cr in Q4 and 20% to Rs 380 Cr for FY26, with margins also...
Syngene's Q3 FY26 revenue dipped slightly to Rs 91.71 Cr, down 3% YoY, while profit (PAT ex-items) fell significantly by 44% to Rs 7.29 Cr. For the nine months, revenue saw modest 3% growth to Rs 270.22 Cr, but profit declined 22% to Rs 22.67 Cr. Operating EBITDA margins were...
Syngene's T&CR (Translational & Clinical Research) business is positioned in a booming global Clinical CRO market, estimated at $59 billion in 2024 and projected to reach $99 billion by 2029 (11% CAGR). India's clinical CRO segment shines, forecast for 16% CAGR ($1.9 billion in 2024 to $3.4 billion by 2028),...
Syngene reported revenue of ₹910.6 Cr for the quarter, a 2% YoY increase, while profit after tax (PAT) before exceptional items saw a 37% YoY decline to ₹67.1 Cr. For the half-year, revenue grew 6% YoY to ₹1,785.1 Cr, with PAT before exceptional items dipping 4% YoY to ₹153.8 Cr....